Nd Cambridge News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive symptoms and sleep. BNC210 was well-tolerated with a safety profile supporting chronic administration. Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD. Webcast and conference call was held 28 September 2023 at 8:00 AM EST (10:00 PM AEST). Please click on the link to watch the replay: http...

HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for CyclASol (cyclosporine ophthalmic solution), a proposed novel treatment for the signs and symptoms of dry eye disease (DED). CyclASol has demonstrated in two pivotal studies fast onset of therapeutic effect in the indication, clinical meaningful improvemen...

All things. steve, meet amy. >> good evening to you both. >> hi, steve. >> ready for the first question? >> i am. >> tuesday's show. on tuesday's show, we talked about the letter to iran in which 47 republican u.s. senators try to school iran's leaders about the u.s. constitution. we also reported that the president of iran holds a ph.d. from a highly regarded western university. so this is your question. where did iranian president rouhani get his ph.d.? a, sweden, b, canada, c, scotland, or d, cambridge, mass, he's a harvard guy. >> i'll go with d. >> cambridge, mass, he's a harvard guy. did...